Pharming Group NV releases transcript of Q2/1H 2026 results call

• Pharming discussed its Q2/1H 2026 results on a July 30 call attended by CEO Fabrice Chouraqui, CCO Leverne Marsh, CMO Anurag Relan, CFO Kenneth Lynard.
• Full-year revenue guidance cut by USD 30 million to USD 375 million-USD 395 million; operating expense outlook lowered to USD 315 million-USD 320 million.
• Q2 revenue USD 90.2 million; RUCONEST USD 72.3 million, down 10% year-over-year, Joenja USD 17.9 million, up 40%.
• RUCONEST active patient base held at about 93% of prior-year level; 84 new patient enrollments, 17 new prescribers; return to growth expected in H2.
• Joenja: 132 US patients on paid therapy; identified US APDS patients rose to 298; October 24 PDUFA for 40/50 mg doses, sNDA for 20/30 mg doses submitted today.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.